Tamoxifen and ovarian cysts: a prospective study

Eur J Obstet Gynecol Reprod Biol. 2001 Dec 10;100(1):77-80. doi: 10.1016/s0301-2115(01)00445-6.

Abstract

Purpose: To prospectively follow a group of women with breast cancer on tamoxifen for the development of ovarian cysts.

Methods: 72 women were followed every 6 months with pelvic examination and vaginal ultrasound. Chi square and Student's t-test were used for statistical analysis.

Results: The duration of treatment was 31.5+/-20 months. The mean age was 51.2+/-9.8 years. 55.6% were post-menopausal. Out of 72 women, 18 (25%) developed ovarian cysts. The mean age of women who developed ovarian cysts was significantly lower than in those who did not (47.0+/-7.0 and 52.5+/-10.2 years, respectively, P=0.03), however, the mean duration of treatment was not significantly different (33.3+/-17.4 and 29.3+/-20 months, respectively, P=0.45). Out of 32, 14 (43.8%) pre-menopausal and out of 40, 4 (10%) post-menopausal women developed ovarian cysts (P=0.003). They developed the cysts after an average duration of 33.3+/-18 and 50.7+/-6.2 months, respectively (P=0.7). The average diameter of the cysts was 2.8+/-1.2 cm. All cysts were simple except for one pre-menopausal women. All the cysts in post-menopausal women resolved spontaneously. One pre-menopausal patient had a multi-loculated cyst, was operated and had a serious cystadenoma. In nine patients, the cysts resolved spontaneously and in three after discontinuation of tamoxifen, and one patient was lost to follow-up. All cysts were asymptomatic.

Conclusion: Ovarian cysts frequently develop in women with breast cancer on tamoxifen. The majority of the cysts resolve spontaneously, therefore an expectant management with follow-up ultrasonography is recommended.

MeSH terms

  • Adult
  • Breast Neoplasms / drug therapy
  • Estrogen Antagonists / adverse effects*
  • Female
  • Humans
  • Middle Aged
  • Ovarian Cysts / chemically induced*
  • Ovarian Cysts / diagnostic imaging
  • Postmenopause
  • Premenopause
  • Prospective Studies
  • Tamoxifen / adverse effects*
  • Time Factors
  • Ultrasonography

Substances

  • Estrogen Antagonists
  • Tamoxifen